CRISPR Therapeutics is a biopharmaceutical company established in 2013 and based in the United States. The company is at the forefront of gene editing, leveraging the groundbreaking CRISPR/Cas9 platform to develop revolutionary gene-based treatments for severe diseases. This technology enables precise modifications to genomic DNA, offering a promising approach to addressing a broad spectrum of conditions, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
Notably, CRISPR Therapeutics has forged strategic partnerships with prominent industry players such as Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc. to expedite and diversify its therapeutic programs. Headquartered in Zug, Switzerland, the company also operates a wholly-owned U.S. subsidiary in Cambridge, Massachusetts, with business offices in San Francisco, California and London, United Kingdom.
In February 2024, CRISPR Therapeutics secured a significant $280.00M Post-IPO Equity investment from EcoR1 Capital and SR One, reflecting robust investor confidence in the company's pioneering gene editing capabilities and its potential to deliver impactful medical solutions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $280.00M | 2 |
|
13 Feb 2024 |
| Grant | Unknown | 1 |
|
14 Dec 2020 |
| Series B | $38.00M | 4 |
|
24 Jun 2016 |
| Series B | $29.00M | 7 |
|
30 Apr 2015 |
| Series A | $35.00M | 5 |
|
29 Apr 2015 |
No recent news or press coverage available for CRISPR Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
